ClinicalTrials.gg
CompletedNCT03428217CANTATAUpdated Mar 20, 2023Results posted

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

A Phase 2 interventional study of CB-839 and Cabozantinib in Advanced Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by Calithera Biosciences, Inc. Completed at 133 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-20.

Sponsored by Calithera Biosciences, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
70th of 1,008
444 · median 40
Started
2018
with 49 others
Phase 2
382 of 1,142
45 open now
Registered
716th of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 70th largest by enrollment of the 1,008 interventional ones that give a count, is one of 50 that started in 2018, is one of 382 in phase 2, and was the 716th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).

03

Conditions studied

  • Advanced Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma

Keywords

  • Tumor Metabolism
  • RCC
  • Glutaminase Inhibitor
  • CB-839
  • CANTATA
  • TKI
  • Tyrosine Kinase Inhibitor
  • cabozantinib
  • Cabometyx
  • Cometriq
  • glutaminase
  • glutamine
  • renal cell
  • clear cell
  • kidney cancer
  • cMET
  • MET
  • HGFR
  • telaglenastat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component
  2. Adult patients
  3. Performance Score (KPS) ≥ 70%
  4. per version 1.1 (RECIST v1.1)
  5. 1-2 for advanced or renal cell carcinoma (RCC) including one anti-angiogenic therapy (any vascular endothelial growth factor [VEGF] pathway-targeted agent used either as monotherapy or as a component of a combination regimen) OR the combination regimen of nivolumab + ipilimumab
  6. Adequate hepatic, renal, cardiac and hematologic function

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with cabozantinib (or other mesenchymal-epithelial transition [MET] inhibitor) or CB-839
  2. Receipt of other anticancer therapy within 2-6 weeks, depending on the treatment
  3. Untreated or active or central nervous system cancer, as defined per protocol
  4. Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug
  5. Known active infection with (HIV), or C virus
  6. Inability to discontinue proton-pump-inhibitor use before randomization
  7. Patients who are pregnant or lactating
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
444 participants (actual)

Study arms

  • Placebo comparator
    Pbo-Cabo

    Placebo twice daily (BID) + cabozantinib (60 mg once daily \[QD\]) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or unacceptable toxicity, whichever occurred first.

    Drug: Cabozantinib · Drug: Placebo

  • Experimental
    CB-Cabo

    CB-839 800 mg BID + cabozantinib (60 mg QD) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per RECIST v1.1 or unacceptable toxicity, whichever occurred first.

    Drug: CB-839 · Drug: Cabozantinib

Interventions

  • DrugCB-839

    Oral glutaminase inhibitor

    Also known as: telaglenastat

  • Oral receptor tyrosine kinase inhibitor

    Also known as: Cabometyx, Cabometriq

  • DrugPlacebo

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)

    PFS is defined as the time from randomization to the occurrence of disease progression as assessed by the IRC using RECIST v1.1 or death from any cause, whichever occurs first. Subjects not experiencing disease progression or death at the time of analysis of PFS will be censored at the date of the last evaluable radiographic disease assessment. RECIST v1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for PFS was 22.14 months.

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause. Estimated from Kaplan-Meier methodology. 95% confidence interval (CI) based on Brookmeyer-Crowley methodology.

    Time frame: Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for OS was 25.86 months.

  2. PFS as Assessed by the Investigator

    PFS is defined as the time from randomization to the occurrence of disease progression as assessed by the IRC using RECIST v1.1 or death from any cause, whichever occurs first. Subjects not experiencing disease progression or death at the time of analysis of PFS will be censored at the date of the last evaluable radiographic disease assessment. RECIST v1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for PFS was 22.64 months.

07

Results

Posted Mar 20, 2023

Participant flow

Participant flow — Overall Study
MilestonePbo-CaboCB-Cabo
Started223221
Received at least 1 dose of study drug221221
Completed00
Not completed223221
Withdrew: Death8993
Withdrew: Withdrawal by subject87
Withdrew: Lost to follow-up13
Withdrew: Study terminated by sponsor124118
Withdrew: Other, not specified10

Outcome measures

PrimaryProgression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)

PFS is defined as the time from randomization to the occurrence of disease progression as assessed by the IRC using RECIST v1.1 or death from any cause, whichever occurs first. Subjects not experiencing disease progression or death at the time of analysis of PFS will be censored at the date of the last evaluable radiographic disease assessment. RECIST v1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for PFS was 22.14 months.
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)
monthsPbo-CaboCB-Cabo
Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)9.33 (7.64 to 11.01)9.17 (7.59 to 11.10)
Statistical analysis
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.6528 · Hazard ratio (hr): 0.94 · 95% CI 0.74 to 1.21
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.8193 · Hazard ratio (hr): 0.97 · 95% CI 0.76 to 1.24
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.8345 · Hazard ratio (hr): 0.97 · 95% CI 0.76 to 1.25
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.9479 · Hazard ratio (hr): 0.99 · 95% CI 0.78 to 1.27
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death due to any cause. Estimated from Kaplan-Meier methodology. 95% confidence interval (CI) based on Brookmeyer-Crowley methodology.

Time frame:
Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for OS was 25.86 months.
Reported as:
Median · months
Overall Survival (OS)
monthsPbo-CaboCB-Cabo
Overall Survival (OS)24.84 (21.59 to NA)22.24 (18.56 to NA)
Statistical analysis
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.3867 · Hazard ratio (hr): 1.15 · 95% CI 0.83 to 1.6
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.3367 · Hazard ratio (hr): 1.17 · 95% CI 0.85 to 1.62
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.2416 · Hazard ratio (hr): 1.22 · 95% CI 0.88 to 1.69
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.3043 · Hazard ratio (hr): 1.19 · 95% CI 0.86 to 1.64
SecondaryPFS as Assessed by the Investigator

PFS is defined as the time from randomization to the occurrence of disease progression as assessed by the IRC using RECIST v1.1 or death from any cause, whichever occurs first. Subjects not experiencing disease progression or death at the time of analysis of PFS will be censored at the date of the last evaluable radiographic disease assessment. RECIST v1.1 criteria: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for PFS was 22.64 months.
Reported as:
Median · months
PFS as Assessed by the Investigator
monthsPbo-CaboCB-Cabo
PFS as Assessed by the Investigator8.38 (6.34 to 9.79)9.17 (7.49 to 9.46)
Statistical analysis
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.9692 · Hazard ratio (hr): 1.00 · 95% CI 0.79 to 1.25
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.9235 · Hazard ratio (hr): 1.01 · 95% CI 0.8 to 1.27
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.9549 · Hazard ratio (hr): 1.01 · 95% CI 0.8 to 1.26
  • Pbo-Cabo vs CB-Cabo · Log Rank · p = 0.8193 · Hazard ratio (hr): 1.03 · 95% CI 0.82 to 1.29

Adverse events

Collected over All-cause mortality: for a maximum follow-up period of 25.86 months; Intent to Treat Population. Adverse events: From first dose of study drug through at least 28 days after last dose of all study treatments, or until initiation of a new anticancer therapy (if earlier). Overall median duration of safety follow-up was 280.0 days. Safety Analysis Population (all participants who received any study drug, analyzed according to the actual treatment received; 4 Pbo-Cabo participants received CB-Cabo).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pbo-Cabo89/223 (39.9%)74/217 (34.1%)213/217 (98.2%)
CB-Cabo93/221 (42.1%)90/225 (40%)222/225 (98.7%)
Most frequent serious events
Showing 10 of 150
Most frequent serious events
EventPbo-CaboCB-Cabo
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/2175/225
DiarrhoeaGastrointestinal disorders2/2176/225
Pleural effusionRespiratory, thoracic and mediastinal disorders1/2175/225
Acute kidney injuryRenal and urinary disorders4/2172/225
DyspnoeaRespiratory, thoracic and mediastinal disorders2/2174/225
CholecystitisHepatobiliary disorders3/2171/225
DehydrationMetabolism and nutrition disorders3/2172/225
HyponatraemiaMetabolism and nutrition disorders3/2172/225
PneumoniaInfections and infestations3/2172/225
Urinary tract infectionInfections and infestations3/2171/225
Most frequent other events
Showing 10 of 69
Most frequent other events
EventPbo-CaboCB-Cabo
DiarrhoeaGastrointestinal disorders160/217162/225
NauseaGastrointestinal disorders118/217123/225
FatigueGeneral disorders109/21794/225
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders87/21795/225
Decreased appetiteMetabolism and nutrition disorders86/21783/225
HypertensionVascular disorders72/21782/225
VomitingGastrointestinal disorders75/21777/225
Weight decreasedInvestigations65/21777/225
ConstipationGastrointestinal disorders63/21769/225
HypothyroidismEndocrine disorders56/21766/225

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pbo-CaboCB-CaboTotal
Mean61.7 ± 10.3360.6 ± 10.3761.2 ± 10.36
Sex: Female, Male
Sex: Female, Male(Participants)Pbo-CaboCB-CaboTotal
Female6847115
Male155174329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pbo-CaboCB-CaboTotal
Hispanic or Latino141125
Not Hispanic or Latino173176349
Unknown or Not Reported363470
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pbo-CaboCB-CaboTotal
White176174350
Not Reported313263
Other, Not Specified3912
Black or African American639
Asian628
Native Hawaiian or Other Pacific Islander112
Stratification Factor: Prior PD-1/PD-L1 Inhibitor Therapy
Stratification Factor: Prior PD-1/PD-L1 Inhibitor Therapy(Participants)Pbo-CaboCB-CaboTotal
Yes139137276
No8484168
Stratification Factor: IMDC Category
Stratification Factor: IMDC Category(Participants)Pbo-CaboCB-CaboTotal
Poor353570
Intermediate149147296
Favorable393978
08

Study locations

133 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Cancer Center
    Phoenix, Arizona 85054, United States
  • The University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
    Los Angeles, California 90048, United States
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
  • Salinas Valley Memorial Healthcare System
    Salinas, California 93901, United States
  • St. Joseph Heritage Healthcare
    Santa Rosa, California 95403, United States
  • Penrose Cancer Center, Research Department
    Colorado Springs, Colorado 80907, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • University of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • H.Lee Moffitt Cancer & Research Institute (Moffitt Cancer Center)
    Tampa, Florida 33612, United States
  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Georgia Cancer Center at Augusta University
    Augusta, Georgia 30912, United States
  • Northwest Georgia Oncology Centers, PC
    Marietta, Georgia 30060, United States
  • St. Luke's Mountain States Tumor Institute
    Boise, Idaho 83712, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • AMITA Health Cancer Institute & Outpatient Center
    Hinsdale, Illinois 60521, United States
  • Orchard Healthcare Research, Inc.
    Skokie, Illinois 60077, United States
  • Northwestern Medicine Cancer Center Warrenville
    Warrenville, Illinois 60555, United States
  • Goshen Center for Cancer Care
    Goshen, Indiana 46526, United States
  • East Jefferson General Hospital
    Metairie, Louisiana 70006, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Maryland, Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • HealthPartners Institute, Regions Cancer Care Center
    Saint Paul, Minnesota 55101, United States
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Mercy Hospital
    Joplin, Missouri 64804, United States
  • HCA Midwest Health
    Kansas City, Missouri 64132, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • San Juan Oncology Associates, PC
    Farmington, New Mexico 87401, United States
  • Roswell Park Cancer Center
    Buffalo, New York 14263, United States
  • North Shore Hematology Oncology Associates PC dba NY Cancer and Blood Specialists
    East Setauket, New York 11733, United States
  • NYU Winthrop Hospital
    Mineola, New York 11501, United States
  • Northern Westchester Hospital
    Mount Kisco, New York 10549, United States
  • Stony Brook Cancer Center
    Stony Brook, New York 11794, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • INTEGRIS Cancer Institute of Oklahoma Proton Campus
    Oklahoma City, Oklahoma 73142, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Saint Francis Hospital Cancer Center
    Greenville, South Carolina 29607, United States
  • West Cancer Center
    Germantown, Tennessee 38138, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Kadlec Clinic Hematology and Oncology
    Kennewick, Washington 99336, United States
  • Froedtert Hospital and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Southern Highlands Private Hospital (Cancer Centre)
    Bowral, New South Wales 2576, Australia
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • MacQuarie University Hospital
    North Ryde, New South Wales 2109, Australia
  • Liverpool Hospital
    Sydney, New South Wales 2170, Australia
  • Tweed Hospital
    Tweed Heads, New South Wales 2485, Australia
  • Pindara Private Hospital
    Benowa, Queensland 4217, Australia
  • Cairns Hospital
    Cairns, Queensland 4870, Australia
  • Mater Misericordiae Limited - Division of Cancer Services
    South Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Ballarat Health Services
    Ballarat, Victoria 3350, Australia
  • Peninsula Private Hospital
    Frankston, Victoria 3199, Australia
  • Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Goulburn Valley Health
    Shepparton, Victoria 3630, Australia
  • Hollywood Private Hospital
    Nedlands, Western Australia 6009, Australia
  • Centre hospitalier régional universitaire (CHRU) de Besançon - Jean-Minjoz
    Besançon, 25030, France
  • CHU de Bordeaux Hôpital Saint André
    Bordeaux, 33000, France
  • Centre François Baclesse
    Caen Cedex 5, 14076, France
  • Centre Jean Perrin
    Clermont Ferrand, 63011, France
  • Centre hospitalier universitaire (CHU) Henri-Mondor
    Créteil, 94010, France
  • Centre Georges-François Leclerc
    Dijon, 21079, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • Institut Paoli-Calmettes Service d'Urologie
    Marseille, 13009, France
  • Institut de Cancérologie de Montpellier (ICM)
    Montpellier, 34298, France
  • Centre Antoine Lacassagne
    Nice, 06189 Nice Cedex 2, France
  • Hôpital Européen Georges-Pompidou (HEGP)
    Paris, 75015, France
  • Institut de Cancérologie de l'Ouest (ICO) - Centre René Gauducheau
    Saint-Herblain, 44805, France
  • CHU de Strasbourg (Les Hôpitaux Universitaires de Strasbourg)
    Strasbourg, 67091, France
  • IUCTO Bureau des Essais Cliniques (Institut Claudius Regaud)
    Toulouse, 31059, France
  • Institut de Cancérologie de Lorraine
    Vandœuvre-lès-Nancy, CS 30519 54519, France
  • Institut Gustave Roussy - Le département de Medecine oncologique
    Villejuif Cedex, 94805, France
  • Medical University Heidelberg, NCT (National Center for Tumour Diseases), Medical Oncology
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • Technischen Universitat München - Urologische Klinik
    München, Bavaria 81675, Germany
  • Charité Universitätsmedizin Berlin, Dept. of Interdisciplinary Urology
    Berlin, 10117, Germany
  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik und Poliklinik
    Dresden, 01307, Germany
  • Universitätsklinikum Essen (AöR) Westdeutsches Tumorzentrum
    Essen, 45147, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitätsklinikum Tübingen, Klinik für Urologie
    Tübingen, 72076, Germany
  • Presidio Ospedaliero Antonio Perrino - U.O.C. Oncologia Medica
    Brindisi, 72100, Italy
  • S.C. Oncologia - ASST Cremona P.O. Ospedale di Cremona
    Cremona, 26100, Italy
  • U.O.C. ASST Santi Paolo e Carlo - Ospedale San Carlo Borromeo
    Milano, 20153, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy

Showing the first 100 of 133 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepulveda Sanchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1411-1418. doi: 10.1001/jamaoncol.2022.3511. PubMed 36048457 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2020, 28 months.

Results were first posted in Mar 2023, 2 years 6 months after primary completion. A results delay was requested in Aug 2021.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 28 months is below that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Feb 9, 2018
StartActual
Apr 24, 2018
Primary completionActual
Aug 31, 2020
CompletionActual
Jul 16, 2021
Results delay requested
Aug 16, 2021
Results first posted
Mar 20, 2023
Last update
Mar 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03428217
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
Apr 24, 2018
Primary completion
Aug 31, 2020
Completion
Jul 16, 2021
Results posted
Mar 20, 2023
Last update
Mar 20, 2023

Study contacts

Sam Whiting, M.D., Ph.D.
study director · Calithera Biosciences, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CB-839

Start the discussion